New therapeutic approaches for treatment-resistant schizophrenia: A look to the future

Journal of Psychiatric Research

Volumn 58, Issue , 2014, Pages 1-6

  Miyamoto, Seiya ^a   Fredrik Jarskog, L ^b   Wolfgang Fleischhacker, W ^c  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Clozapine; Electroconvulsive therapy; Repetitive transcranial magnetic stimulation; Schizophrenia; Transcranial direct current stimulation; Treatment resistant schizophrenia

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; CYCLOSERINE; ESTRADIOL; FLUOXETINE; GLYCINE; HALOPERIDOL; LAMOTRIGINE; MIRTAZAPINE; PIMOZIDE; RISPERIDONE; SARCOSINE; SERINE; SERTINDOLE; SULPIRIDE; TETRABENAZINE; TOPIRAMATE; NEUROLEPTIC AGENT;

DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; HUMAN; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; TRANSCRANIAL DIRECT CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESISTANT SCHIZOPHRENIA; PROCEDURES; TRENDS;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; SCHIZOPHRENIA; TRANSCRANIAL DIRECT CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84912520568     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.07.001     Document Type: Review

References (69)

1. Afshar H., Roohafza H., Mousavi G., Golchin S., Toghianifar N., Sadeghi M., et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. JPsychopharmacol 2009, 23:157-162.
2. Andrade C. Transcranial direct current stimulation for refractory auditory hallucinations in schizophrenia. JClin Psychiatry 2013, 74:e1054-1058.
3. Antal A., Nitsche M.A., Paulus W. Transcranial direct current stimulation and the visual cortex. Brain Res Bull 2006, 68:459-463.
4. Arnone D. Review of the use of Topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry 2005, 4:5.
5. Bandelow B., Zohar J., Kasper S., Moller H.J. How to grade categories of evidence. World J Biol Psychiatry 2008, 9:242-247.
6. Barbui C., Signoretti A., Mule S., Boso M., Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment?. Schizophr Bull 2009, 35:458-468.
7. Barker A.T., Jalinous R., Freeston I.L. Non-invasive magnetic stimulation of human motor cortex. Lancet 1985, 1:1106-1107.
8. Barretto E.M., Kayo M., Avrichir B.S., Sa A.R., Camargo M., Napolitano I.C., et al. Apreliminary controlled trial of cognitive behavioral therapy in clozapine-resistant schizophrenia. JNerv Ment Dis 2009, 197:865-868.
9. Behdani F., Hebrani P., Rezaei Ardani A., Rafee E. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial. Arch Iran Med 2011, 14:270-275.
10. Bellucci D.M., Glaberman K., Haslam N. Computer-assisted cognitive rehabilitation reduces negative symptoms in the severely mentally ill. Schizophr Res 2003, 59:225-232.
11. Braga R.J., Mendelowitz A.J., Fink M., Schooler N.R., Bailine S.H., Malur C., et al. Arandomized controlled trial of ECT in clozapine-refractory schizophrenia. Biol Psychiatry 2009, 64:212S-213S.
12. Brunelin J., Mondino M., Gassab L., Haesebaert F., Gaha L., Suaud-Chagny M.F., et al. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry 2012, 169:719-724.
13. Brunoni A.R., Nitsche M.A., Bolognini N., Bikson M., Wagner T., Merabet L., et al. Clinical research with transcranial direct current stimulation (tDCS): challenges and future directions. Brain Stimul 2012, 5:175-195.
14. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010, 36:71-93.
15. Conley R.R., Kelly D.L. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001, 50:898-911.
16. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996, 3:241-253.
17. Cunningham M.O., Jones R.S. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex invitro. Neuropharmacology 2000, 39:2139-2146.
18. de Jesus D.R., Gil A., Barbosa L., Lobato M.I., Magalhaes P.V., Favalli G.P., et al. Apilot double-blind sham-controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Res 2011, 188:203-207.
19. Fasano A., Bentivoglio A.R. Tetrabenazine. Expert Opin Pharmacother 2009, 10:2883-2896.
20. Frankenburg F.R., Suppes T., McLean P.E. Combined clozapine and electroconvulsive therapy. Convuls Ther 1993, 9:176-180.
21. Goff D.C., Leahy L., Berman I., Posever T., Herz L., Leon A.C., et al. Aplacebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. JClin Psychopharmacol 2001, 21:484-487.
22. Häfner H., Behrens S., De Vry J., Gattaz W.F. An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia. Psychiatr Res 1991, 38:125-134.
23. Hahn M.K., Cohn T., Teo C., Remington G. Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. Clin Schizophr Relat Psychoses 2013, 6:186-196.
24. Hasan A., Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012, 13:318-378.
25. Hoffman R.E., Boutros N.N., Berman R.M., Roessler E., Belger A., Krystal J.H., et al. Transcranial magnetic stimulation of left temporoparietal cortex in three patients reporting hallucinated "voices". Biol Psychiatry 1999, 46:130-132.
26. Hoogendam J.M., Ramakers G.M., Di Lazzaro V. Physiology of repetitive transcranial magnetic stimulation of the human brain. Brain Stimul 2010, 3:95-118.
27. Insel T.R. Rethinking schizophrenia. Nature 2010, 468:187-193.
28. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148:1301-1308.
29. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988, 45:789-796.
30. Kho K.H., Blansjaar B.A., de Vries S., Babuskova D., Zwinderman A.H., Linszen D.H. Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia-an open label study. Eur Arch Psychiatry Clin Neurosci 2004, 254:372-379.
31. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199-214.
32. Kulkarni J., Gavrilidis E., Wang W., Worsley R., Fitzgerald P.B., Gurvich C., et al. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry 2014.
33. Lan G.X., Li Z.C., Li L. Arandomized, placebo-controlled clinical trial of combined citalopram and clozapine in the treatment of negative symptoms of schizophrenia. Clin Ment Health J 2006, 20:696-698.
34. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 2000, 31:371-384.
35. Lieberman J.A. Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. JClin Psychiatry 1999, 60(Suppl.12):9-12.
36. Lieberman J.A., Sheitman B.B., Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997, 17:205-229.
37. Lingjaerde O. Tetrabenazine (nitoman) in the treatment of psychoses: with a discussion on the central mode of action of tetrabenazine and reserpine. Acta Psychiatr Scand 1963, 39(Suppl.170):1-109.
38. Lolas F. Brain polarization: behavioral and therapeutic effects. Biol Psychiatry 1977, 12:37-47.
39. Lyon G.J., Abi-Dargham A., Moore H., Lieberman J.A., Javitch J.A., Sulzer D. Presynaptic regulation of dopamine transmission in schizophrenia. Schizophr Bull 2011, 37:108-117.
40. Masoudzadeh A., Khalilian A.R. Comparative study of clozapine, electroshock and the combination of ECT with clozapine in treatment-resistant schizophrenic patients. Pak J Biol Sci 2007, 10:4287-4290.
41. Matheson S.L., Green M.J., Loo C., Carr V.J. Quality assessment and comparison of evidence for electroconvulsive therapy and repetitive transcranial magnetic stimulation for schizophrenia: a systematic meta-review. Schizophr Res 2010, 118:201-210.
42. McIlwain M.E., Harrison J., Wheeler A.J., Russell B.R. Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatr Dis Treat 2011, 7:135-149.
43. Miyamoto S., LaMantia A.S., Duncan G.E., Sullivan P., Gilmore J.H., Lieberman J.A. Recent advances in the neurobiology of schizophrenia. Mol Interv 2003, 3:27-39.
44. Miyamoto S., Miyake N., Jarskog L.F., Fleischhacker W.W., Lieberman J.A. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 2012, 17:1206-1227.
45. Mizuno Y., Suzuki T., Nakagawa A., Yoshida K., Mimura M., Fleischhacker W.W., et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2014.
46. Muscatello M.R., Bruno A., Pandolfo G., Mico U., Bellinghieri P.M., Scimeca G., et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. JPsychopharmacol 2011, 25:667-674.
47. Nielsen J., Emborg C., Gydesen S., Dybbro J., Aagaard J., Haderup K., et al. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study. JClin Psychopharmacol 2012, 32:173-178.
48. Nitsche M.A., Cohen L.G., Wassermann E.M., Priori A., Lang N., Antal A., et al. Transcranial direct current stimulation: state of the art 2008. Brain Stimul 2008, 1:206-223.
49. Petrides G. Adding electroconvulsive therapy (ECT) to clozapine is an effective treatment for patients with clozapine-resistant schizophrenia. Presented at New Clinical Drug Evaluation Unit (NCDEU) 50th Anniversary Meeting. Boca Raton, FL; 2010.
50. Porcelli S., Balzarro B., Serretti A. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 2012, 22:165-182.
51. Poulet E., Brunelin J., Kallel L., Bediou B., Dalery J., D'Amato T., et al. Is rTMS efficient as a maintenance treatment for auditory verbal hallucinations? A case report. Schizophr Res 2006, 84:183-184.
52. Remington G., Kapur S., Foussias G., Agid O., Mann S., Borlido C., et al. Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial. JClin Psychopharmacol 2012, 32:95-99.
53. Saha S., Chant D., Welham J., McGrath J. Asystematic review of the prevalence of schizophrenia. PLoS Med 2005, 2:e141.
54. Shank R.P., Gardocki J.F., Streeter A.J., Maryanoff B.E. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000, 41(Suppl.1):S3-S9.
55. Siebner H.R., Rothwell J. Transcranial magnetic stimulation: new insights into representational cortical plasticity. Exp Brain Res 2003, 148:1-16.
56. Slotema C.W., Aleman A., Daskalakis Z.J., Sommer I.E. Meta-analysis of repetitive transcranial magnetic stimulation in the treatment of auditory verbal hallucinations: update and effects after one month. Schizophr Res 2012, 142:40-45.
57. Slotema C.W., Blom J.D., Hoek H.W., Sommer I.E. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. JClin Psychiatry 2010, 71:873-884.
58. Slotema C.W., Blom J.D., van Lutterveld R., Hoek H.W., Sommer I.E. Review of the efficacy of transcranial magnetic stimulation for auditory verbal hallucinations. Biol Psychiatry 2014, 76:101-110.
59. Sommer I.E., Begemann M.J., Temmerman A., Leucht S. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 2012, 38:1003-1011.
60. Sommer I.E., Slotema C.W., Daskalakis Z.J., Derks E.M., Blom J.D., van der Gaag M. The treatment of hallucinations in schizophrenia spectrum disorders. Schizophr Bull 2012, 38:704-714.
61. Stewart P.T., Loo C.K., MacPherson R., Hadzi-Pavlovic D. The effect of electrode placement and pulsewidth on asystole and bradycardia during the electroconvulsive therapy stimulus. Int J Neuropsychopharmacol 2011, 14:585-594.
62. Taylor D.M., Smith L., Gee S.H., Nielsen J. Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand 2012, 125:15-24.
63. Thirthalli J., Bharadwaj B., Kulkarni S., Gangadhar B.N., Kharawala S., Andrade C. Successful use of maintenance rTMS for 8 months in a patient with antipsychotic-refractory auditory hallucinations. Schizophr Res 2008, 100:351-352.
64. Tiihonen J., Halonen P., Wahlbeck K., Repo-Tiihonen E., Hyvarinen S., Eronen M., et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. JClin Psychiatry 2005, 66:1012-1015.
65. Tiihonen J., Wahlbeck K., Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 2009, 109:10-14.
66. Turkington D., Sensky T., Scott J., Barnes T.R., Nur U., Siddle R., et al. Arandomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: a five-year follow-up. Schizophr Res 2008, 98:1-7.
67. Vayisoğlu S., Anil Yagcioglu A.E., Yagcioglu S., Karahan S., Karci O., Gurel S.C., et al. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. Schizophr Res 2013, 143:207-214.
68. Wexler B.E., Bell M.D. Cognitive remediation and vocational rehabilitation for schizophrenia. Schizophr Bull 2005, 31:931-941.
69. Zoccali R., Muscatello M.R., Bruno A., Cambria R., Mico U., Spina E., et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res 2007, 93:109-116.